Patents by Inventor Ying-Yung Lok
Ying-Yung Lok has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10781266Abstract: An antibody, or an antigen-binding fragment there, binding human ENO1 (GenBank: AAH506421.1) is provided. Methods for treating an ENO1 protein-related disease or disorder, inhibiting cancer invasion and diagnosis of cancer are also provided.Type: GrantFiled: March 19, 2018Date of Patent: September 22, 2020Assignees: DEVELOPMENT CENTER FOR BIOTECHNOLOGY, NATIONAL HEALTH RESEARCH INSTITUTESInventors: Shih-Chong Tsai, Ta-Tung Yuan, Shih-Chi Tseng, Jiann-Shiun Lai, Chia-Cheng Wu, Po-Yin Lin, Ya-Wei Tsai, Chao-Yang Huang, Ying-Yung Lok, Chung-Hsiun Wu, Hsien-Yu Tsai, Neng-Yao Shih, Ko-Jiunn Liu, Li-Tzong Chen
-
Patent number: 10752688Abstract: An anti-human T-cell immunoglobulin domain and mucin domain 3 (TIM-3) antibody, can bind the peptides, comprising the amino-acid sequence RKGDVSL (SEQ ID NO: 9) and/or EKFNLKL (SEQ ID NO: 10) of human TIM-3 protein. The antibody can regulate immune cell activity. The antibody or binding fragment thereof is useful in diagnosis, prognosis, and treatment of cancers that have been reported to express cell-surface TIM-3 such as lung, liver, esophageal cancer and solid tumors.Type: GrantFiled: December 30, 2017Date of Patent: August 25, 2020Assignee: DEVELOPMENT CENTER FOR BIOTECHNOLOGYInventors: Yu-Chen Yang, Li-Yu Chen, Chia-Hua Li, Pei-Han Tai, Hong-Kai Chen, Ying-Yung Lok, Chih-Yung Hu, Chien-Tsun Kuan, Chung-Hsiun Wu
-
Publication number: 20190322762Abstract: An antibody, or an antigen-binding fragment there, binding human ENO1 (GenBank: AAH506421.1) is provided. Methods for treating an ENO1 protein-related disease or disorder, inhibiting cancer invasion and diagnosis of cancer are also provided.Type: ApplicationFiled: March 19, 2018Publication date: October 24, 2019Applicants: DEVELOPMENT CENTER FOR BIOTECHNOLOGY, NATIONAL HEALTH RESEARCH INSTITUTESInventors: SHIH-CHONG TSAI, TA-TUNG YUAN, SHIH-CHI TSENG, JIANN-SHIUN LAI, CHIA-CHENG WU, PO-YIN LIN, YA-WEI TSAI, CHAO-YANG HUANG, YING-YUNG LOK, CHUNG-HSIUN WU, HSIEN-YU TSAI, NENG-YAO SHIH, KO-JIUNN LIU, LI-TZONG CHEN
-
Publication number: 20180186881Abstract: An anti-human T-cell immunoglobulin domain and mucin domain 3 (TIM-3) antibody, can bind the peptides, comprising the amino-acid sequence RKGDVSL (SEQ ID NO: 9) and/or EKFNLKL (SEQ ID NO: 10) of human TIM-3 protein. The antibody can regulate immune cell activity. The antibody or binding fragment thereof is useful in diagnosis, prognosis, and treatment of cancers that have been reported to express cell-surface TIM-3 such as lung, liver, esophageal cancer and solid tumors.Type: ApplicationFiled: December 30, 2017Publication date: July 5, 2018Applicant: Development Center for BiotechnologyInventors: Yu-Chen Yang, Li-Yu CHEN, Chia-Hua LI, Pei-Han TAI, Hong-Kai CHEN, Ying-Yung LOK, Chih-Yung HU, Chien-Tsun KUAN, Chung-Hsiun WU
-
Patent number: 9527922Abstract: A humanized antibody, or a binding fragment thereof, wherein the humanized antibody binds human ENO1 (GenBank: AAH50642.1), wherein the antibody comprises a light chain variable region (VL) domain comprising a CDR1 having the amino acid sequence LCDR1 (RASENIYSYLT; SEQ ID NO: 6) and a CDR2 having the amino acid sequence LCDR2 (NAKTLPE; SEQ ID NO: 7) and a CDR3 having the amino acid sequence LCDR3 (QHHYGTPYT; SEQ ID NO: 8) and an antibody heavy chain variable region (VH) domain comprising a CDR1 having the amino acid sequence HCDR1 (GYTFTSCVMN; SEQ ID NO: 3), a CDR2 having the amino acid sequence HCDR2 (YINPYNDGTKYNEKFKG; SEQ ID NO: 4) and a CDR3 having the amino acid sequence HCDR3 (EGFYYGNFDN; SEQ ID NO: 5), wherein framework regions in the light chain variable region (VL) domain and the heavy chain variable region (VH) domain comprise amino acid sequences from a human immunoglobulin.Type: GrantFiled: December 31, 2014Date of Patent: December 27, 2016Assignees: Development Center for Biotechnology, DCB-USA LLC, National Health Research InstitutesInventors: Shih-Chong Tsai, Ta-Tung Yuan, Shih-Chi Tseng, Jiann-Shiun Lai, Chia-Cheng Wu, Chao-Yang Huang, Ya-Wei Tsai, Ying-Yung Lok, Chung-Hsiun Wu, Neng-Yao Shih, Ko-Jiunn Liu, Li-Tzong Chen
-
Patent number: 9447193Abstract: A method for treating cancer includes administering to a subject in need thereof an antibody against a transmembrane and coiled-coil domains protein 3 (TMCC3), wherein the antibody binds to an epitope in an extracellular domain of TMCC3. The antibody binds to an epitope in an intercoil domain of TMCC3. A method of diagnosing or assessing a cancer condition includes assessing a level of expression or activity of a transmembrane and coiled-coil domains protein 3 (TMCC3) in a sample, wherein an increase in the level of expression of activity of TMCC3 as compared to a standard indicates the presence of cancer stem cells in the sample.Type: GrantFiled: March 24, 2014Date of Patent: September 20, 2016Assignees: Development Center for Biotechnology, Academia Sinica, Chang Gung Memorial HospitalInventors: Alice L. Yu, John Yu, Ya-Hui Wang, Chuan-Lung Hsu, Yi-Chang Chen, Ying-Yung Lok
-
Patent number: 9428575Abstract: An anti-granulysin antibody, or an scFv or Fab fragment thereof, capable of binding to an epitope region from R64 to R113 of granulysin and capable of neutralizing an activity of granulysin. The antibody may contain a sequence selected from the sequences of SEQ ID NO:82 to SEQ ID NO:195, or the antibody may contain a sequence selected from the sequences of SEQ ID NO:39 to SEQ ID NO:76. The antibody may be a monoclonal antibody. A method for treating or preventing an unwanted immune response disorder includes administering to a subject in need thereof an effective amount of an anti-granulysin antibody capable of neutralizing the activity of granulysin. The unwanted immune response disorder may be SJS, TEN, or GVHD.Type: GrantFiled: December 31, 2013Date of Patent: August 30, 2016Assignees: Development Center for Biotechnology, DCB-USA LLC, Academia SinicaInventors: Jiann-Shiun Lai, Hung-Ling Wang, Chao-Yang Huang, Ying-Yung Lok, Yuan-Tsong Chen, Woan-Eng Chan, Chih-Yung Hu
-
Publication number: 20160185876Abstract: A humanized antibody, or a binding fragment thereof, wherein the humanized antibody binds human ENO1 (GenBank: AAH50642.1), wherein the antibody comprises a light chain variable region (VL) domain comprising a CDR1 having the amino acid sequence LCDR1 (RASENIYSYLT; SEQ ID NO: 6) and a CDR2 having the amino acid sequence LCDR2 (NAKTLPE; SEQ ID NO: 7) and a CDR3 having the amino acid sequence LCDR3 (QHHYGTPYT; SEQ ID NO: 8) and an antibody heavy chain variable region (VH) domain comprising a CDR1 having the amino acid sequence HCDR1 (GYTFTSCVMN; SEQ ID NO: 3), a CDR2 having the amino acid sequence HCDR2 (YINPYNDGTKYNEKFKG; SEQ ID NO: 4) and a CDR3 having the amino acid sequence HCDR3 (EGFYYGNFDN; SEQ ID NO: 5), wherein framework regions in the light chain variable region (VL) domain and the heavy chain variable region (VH) domain comprise amino acid sequences from a human immunoglobulin.Type: ApplicationFiled: December 31, 2014Publication date: June 30, 2016Applicants: Development Center for Biotechnology, DCB-USA LLC, National Health Research InstitutesInventors: Shih-Chong Tsai, Ta-Tung Yuan, Shih-Chi Tseng, Jiann-Shiun Lai, Chia-Cheng Wu, Chao-Yang Huang, Ya-Wei Tsai, Ying-Yung Lok, Chung-Hsiun Wu, Neng-Yao Shih, Ko-Jiunn Liu, Li-Tzong Chen
-
Publication number: 20140363372Abstract: A method for treating cancer includes administering to a subject in need thereof an antibody against a transmembrane and coiled-coil domains protein 3 (TMCC3), wherein the antibody binds to an epitope in an extracellular domain of TMCC3. The antibody binds to an epitope in an intercoil domain of TMCC3. A method of diagnosing or assessing a cancer condition includes assessing a level of expression or activity of a transmembrane and coiled-coil domains protein 3 (TMCC3) in a sample, wherein an increase in the level of expression of activity of TMCC3 as compared to a standard indicates the presence of cancer stem cells in the sample.Type: ApplicationFiled: March 24, 2014Publication date: December 11, 2014Applicants: DEVELOPMENT CENTER FOR BIOTECHNOLOGY, CHANG GUNG MEMORIAL HOSPITAL, ACADEMIA SINICAInventors: Alice L. Yu, John Yu, Ya-Hui Wang, Chuan-Lung Hsu, Yi-Chang Chen, Ying-Yung Lok
-
Publication number: 20140186352Abstract: An anti-granulysin antibody, or an scFv or Fab fragment thereof, capable of binding to an epitope region from R64 to R113 of granulysin and capable of neutralizing an activity of granulysin. The antibody may contain a sequence selected from the sequences of SEQ ID NO:82 to SEQ ID NO:195, or the antibody may contain a sequence selected from the sequences of SEQ ID NO:39 to SEQ ID NO:76. The antibody may be a monoclonal antibody. A method for treating or preventing an unwanted immune response disorder includes administering to a subject in need thereof an effective amount of an anti-granulysin antibody capable of neutralizing the activity of granulysin. The unwanted immune response disorder may be SJS, TEN, or GVHD.Type: ApplicationFiled: December 31, 2013Publication date: July 3, 2014Applicant: DEVELOPMENT CENTER FOR BIOTECHNOLOGYInventors: Jiann-Shiun Lai, Hung-Ling Wang, Chao-Yang Huang, Ying-Yung Lok